Progressive supranuclear palsy

A survey of the disease course

Pilar Santacruz, Bob Uttl, Irene Litvan, Jordan Grafman*

*Corresponding author for this work

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Background: The most accurate knowledge about progressive supranuclear palsy (PSP) comes from small sample studies that preclude precise estimation of the proportion of PSP patients affected with various symptoms and the examination of factors predicting survival time. Objective: To describe the course of PSP in a large clinically diagnosed sample of PSP patients and to identify factors predicting survival time. Methods: We surveyed the caregivers of 318 living and 119 deceased patients with progressive supranuclear palsy. The main outcome measures were a principal symptom severity questionnaire and a signs and symptoms questionnaire. Results: The estimated age of PSP symptom onset depends critically on how symptom onset is defined, with estimates differing by as much as 1.5 years. Men and women were represented equally (51.6% versus 48.4%) in the living sample, but men formed 61.8% of the deceased sample. Men were diagnosed later than women following symptom onset (33.4 versus 24.1 months) and died earlier following the diagnosis (37.0 versus 47.6 months). Motor and visual symptoms appeared first, followed by emotional and personality problems, cognitive impairment, and sleep changes. Whereas motor symptoms eventually affected almost every patient, emotional/personality and cognitive symptoms did not. The early onset, presence of falls, slowness, and inability to move eyes downward early in the development of the disease predicted survival time. Conclusion: PSP is a rapidly progressive disease dominated by motor symptoms, and it affects men more frequently than women.

Original languageEnglish (US)
Pages (from-to)1637-1647
Number of pages11
JournalNeurology
Volume50
Issue number6
DOIs
StatePublished - Jan 1 1998

Fingerprint

Progressive Supranuclear Palsy
Survival
Personality
Neurobehavioral Manifestations
Surveys and Questionnaires
Caregivers
Signs and Symptoms
Early Diagnosis
Sleep
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Santacruz, Pilar ; Uttl, Bob ; Litvan, Irene ; Grafman, Jordan. / Progressive supranuclear palsy : A survey of the disease course. In: Neurology. 1998 ; Vol. 50, No. 6. pp. 1637-1647.
@article{af65b02c06b34cb1b13042a7fbfd82c9,
title = "Progressive supranuclear palsy: A survey of the disease course",
abstract = "Background: The most accurate knowledge about progressive supranuclear palsy (PSP) comes from small sample studies that preclude precise estimation of the proportion of PSP patients affected with various symptoms and the examination of factors predicting survival time. Objective: To describe the course of PSP in a large clinically diagnosed sample of PSP patients and to identify factors predicting survival time. Methods: We surveyed the caregivers of 318 living and 119 deceased patients with progressive supranuclear palsy. The main outcome measures were a principal symptom severity questionnaire and a signs and symptoms questionnaire. Results: The estimated age of PSP symptom onset depends critically on how symptom onset is defined, with estimates differing by as much as 1.5 years. Men and women were represented equally (51.6{\%} versus 48.4{\%}) in the living sample, but men formed 61.8{\%} of the deceased sample. Men were diagnosed later than women following symptom onset (33.4 versus 24.1 months) and died earlier following the diagnosis (37.0 versus 47.6 months). Motor and visual symptoms appeared first, followed by emotional and personality problems, cognitive impairment, and sleep changes. Whereas motor symptoms eventually affected almost every patient, emotional/personality and cognitive symptoms did not. The early onset, presence of falls, slowness, and inability to move eyes downward early in the development of the disease predicted survival time. Conclusion: PSP is a rapidly progressive disease dominated by motor symptoms, and it affects men more frequently than women.",
author = "Pilar Santacruz and Bob Uttl and Irene Litvan and Jordan Grafman",
year = "1998",
month = "1",
day = "1",
doi = "10.1212/WNL.50.6.1637",
language = "English (US)",
volume = "50",
pages = "1637--1647",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Progressive supranuclear palsy : A survey of the disease course. / Santacruz, Pilar; Uttl, Bob; Litvan, Irene; Grafman, Jordan.

In: Neurology, Vol. 50, No. 6, 01.01.1998, p. 1637-1647.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Progressive supranuclear palsy

T2 - A survey of the disease course

AU - Santacruz, Pilar

AU - Uttl, Bob

AU - Litvan, Irene

AU - Grafman, Jordan

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background: The most accurate knowledge about progressive supranuclear palsy (PSP) comes from small sample studies that preclude precise estimation of the proportion of PSP patients affected with various symptoms and the examination of factors predicting survival time. Objective: To describe the course of PSP in a large clinically diagnosed sample of PSP patients and to identify factors predicting survival time. Methods: We surveyed the caregivers of 318 living and 119 deceased patients with progressive supranuclear palsy. The main outcome measures were a principal symptom severity questionnaire and a signs and symptoms questionnaire. Results: The estimated age of PSP symptom onset depends critically on how symptom onset is defined, with estimates differing by as much as 1.5 years. Men and women were represented equally (51.6% versus 48.4%) in the living sample, but men formed 61.8% of the deceased sample. Men were diagnosed later than women following symptom onset (33.4 versus 24.1 months) and died earlier following the diagnosis (37.0 versus 47.6 months). Motor and visual symptoms appeared first, followed by emotional and personality problems, cognitive impairment, and sleep changes. Whereas motor symptoms eventually affected almost every patient, emotional/personality and cognitive symptoms did not. The early onset, presence of falls, slowness, and inability to move eyes downward early in the development of the disease predicted survival time. Conclusion: PSP is a rapidly progressive disease dominated by motor symptoms, and it affects men more frequently than women.

AB - Background: The most accurate knowledge about progressive supranuclear palsy (PSP) comes from small sample studies that preclude precise estimation of the proportion of PSP patients affected with various symptoms and the examination of factors predicting survival time. Objective: To describe the course of PSP in a large clinically diagnosed sample of PSP patients and to identify factors predicting survival time. Methods: We surveyed the caregivers of 318 living and 119 deceased patients with progressive supranuclear palsy. The main outcome measures were a principal symptom severity questionnaire and a signs and symptoms questionnaire. Results: The estimated age of PSP symptom onset depends critically on how symptom onset is defined, with estimates differing by as much as 1.5 years. Men and women were represented equally (51.6% versus 48.4%) in the living sample, but men formed 61.8% of the deceased sample. Men were diagnosed later than women following symptom onset (33.4 versus 24.1 months) and died earlier following the diagnosis (37.0 versus 47.6 months). Motor and visual symptoms appeared first, followed by emotional and personality problems, cognitive impairment, and sleep changes. Whereas motor symptoms eventually affected almost every patient, emotional/personality and cognitive symptoms did not. The early onset, presence of falls, slowness, and inability to move eyes downward early in the development of the disease predicted survival time. Conclusion: PSP is a rapidly progressive disease dominated by motor symptoms, and it affects men more frequently than women.

UR - http://www.scopus.com/inward/record.url?scp=0031747481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031747481&partnerID=8YFLogxK

U2 - 10.1212/WNL.50.6.1637

DO - 10.1212/WNL.50.6.1637

M3 - Article

VL - 50

SP - 1637

EP - 1647

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -